

**SUPPLEMENTAL INFORMATION
DISCLOSURE CITATION**

(Use several sheets if necessary)
Page 1 of 7

ATTY. DOCKET NO. PC25240A

SERIAL NO. 10/763,340

APPLICANT Timothy A. Hagen, et al.

FILING DATE January 23, 2004

GROUP 1615

U.S. PATENT DOCUMENTS

EXAMINER R INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
RA	US	2	9	5	5	9	5	6	10/11/1960	Baugh, et al.	117	100	
	US	4	0	5	3	2	6	4	10/11/1977	King	425	8	
	US	4	0	8	6	3	4	6	4/25/1978	Bocker, et al.	424	253	
	US	4	0	9	2	0	8	9	5/30/1978	Bocker, et al.	425	10	
	US	4	2	9	3	5	7	0	10/06/1981	Vadasz	426	3	
	US	4	4	7	4	7	6	8	10/02/1984	Bright	424	180	
	US	4	5	1	7	3	5	9	05/14/1985	Kobrehel, et al.	536	7.4	
	US	4	6	7	5	1	4	0	06/23/1987	Sparks, et al.	264	4.3	
	US	4	8	7	4	6	1	1	10/17/1989	Wilson, et al.	424	410	
	US	4	9	3	1	2	8	5	06/05/1990	Edgren, et al.	424	473	
	US	4	9	5	7	6	8	1	09/18/1990	Klimesch, et al.	264	211.23	
	US	4	9	6	3	5	3	1	10/16/1990	Ramington, et al.	514	29	
	US	5	0	1	9	3	0	2	05/28/1991	Sparks, et al.	264	8	
	US	5	0	2	4	8	4	2	06/18/1991	Edgren, et al.	424	473	
	US	5	0	4	7	2	4	4	09/10/1991	Sanvordeker, et al.	424	435	
	US	5	0	6	4	6	5	0	10/12/1991	Lew	424	435	
	US	5	0	8	4	2	8	7	01/28/1992	Ghebre-Sellassie, et al.	424	495	
	US	5	1	0	0	5	9	2	03/31/1992	Sparks, et al.	264	7	
	US	5	1	6	0	7	4	3	11/03/1992	Edgren, et al.	424	473	
	US	5	1	4	3	6	6	2	09/1/1992	Chesterfield, et al.	264	8	
	US	5	1	8	3	6	9	0	02/02/1993	Carr, et al.	427	213.31	
	US	5	1	9	4	2	6	2	03/16/1993	Goldberg, et al.	424	401	
	US	5	1	9	6	1	9	9	03/23/1993	Fulsz	424	401	
	US	5	2	1	3	8	1	0	05/25/1993	Steber	424	490	
	US	5	2	3	6	7	3	4	08/17/1993	Fulsz	426	641	
	US	5	2	9	2	6	5	7	03/08/1994	Rutherford, et al.	435	243	
PA	US	5	3	4	8	7	5	8	09/20/1994	Fulsz, et al.	426	660	

SUPPLEMENTAL INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) Page 2 of 7									ATTY. DOCKET NO. PC25240A			SERIAL NO. 10/763,340		
									APPLICANT Timothy A. Hagen, et al.					
									FILING DATE January 23, 2004			GROUP 1615		
28	US	5	3	8	0	4	7	3	01/10/1995	Bogue, et al.	264	11		
	US	5	4	0	5	6	1	7	04/11/1995	Gowan, Jr., et al.	424	464		
	US	5	4	0	7	6	7	6	04/18/1995	Fuisz	424	401		
	US	5	4	2	9	8	3	6	07/04/1995	Fuisz	426	601		
	US	5	4	3	3	9	5	1	07/18/1995	Serajuddin, et al	424	486		
	US	5	4	5	6	9	3	2	10/10/1995	Fuisz, et al	426	548		
	US	5	5	4	9	9	1	7	08/27/1996	Cherukuri, et al.	426	96		
	US	5	4	6	1	0	8	9	10/24/1995	Handyside, et al.	523	171		
	US	5	5	0	0	1	6	2	03/19/1996	Theisen, et al	264	9		
	US	5	5	0	1	8	5	8	03/26/1996	Fuisz	424	439		
	US	5	5	0	5	9	8	3	04/09/1996	Kamada	427	2.21		
	US	5	5	1	8	7	3	0	05/21/1996	Fuisz	424	426		
	US	5	5	3	9	0	0	0	07/23/1996	Leonard	514	682		
	US	5	5	4	9	9	1	7	08/27/1996	Cherukuri, et al.	426	96		
	US	5	5	5	6	6	5	2	09/17/1996	Cherukari, et al	426	5		
	US	5	5	6	9	4	6	7	10/29/1996	Ruiz	424	489		
	US	5	5	8	2	8	5	5	12/10/1996	Cherukuri	426	5		
	US	5	5	9	7	4	1	6	01/28/1997	Fuisz, et al.	127	30		
	US	5	5	9	7	8	4	4	01/28/1997	Chauhan, et al.	514	400		
	US	5	6	0	1	7	6	1	02/11/1997	Hoffman, et al.	264	4.3		
	US	5	6	8	3	7	2	0	11/04/1997	Myers, et al.	424	489		
	US	5	6	9	0	9	5	9	11/25/1997	Palepu, et al.	424	472		
	US	5	7	0	7	6	4	6	01/13/1998	Yajima, et al.	424	439		
	US	5	7	3	3	5	7	7	03/31/1998	Myers, et al.	424	488		
	US	5	7	4	1	5	1	9	04/21/1998	Rosenberg, et al.	424	464		
	US	5	7	4	4	1	8	0	08/28/1998	Cherukuri, et al	426	99		
	US	5	7	6	6	5	2	1	06/16/1998	Le Thiesse et al.	264	7		
29	US	5	7	9	2	4	7	4	08/11/1998	Rauchfuss	424	489		

SUPPLEMENTAL INFORMATION DISCLOSURE CITATION						ATTY. DOCKET NO. PC25240A				SERIAL NO. 10/763,340			
(Use several sheets if necessary) Page 3 of 7						APPLICANT Timothy A. Hagen, et al.							
						FILING DATE January 23, 2004				GROUP 1615			
PH	US	5	8	2	4	9	4	2	10/20/1998	Cherukuri, et al.	424	464	
	US	5	8	1	0	0	3	4	11/24/1998	Raiden, et al	424	464	
	US	5	8	4	9	2	2	3	12/15/1998	Myers, et al.	264	15	
	US	5	8	5	1	9	5	3	12/22/1998	Myers, et al.	424	464	
	US	5	8	5	1	9	5	5	12/22/1998	Sanghvi, et al.	424	464	
	US	5	8	5	9	9	1	5	01/05/1999	Pinkus	242	486	
	US	5	8	6	9	0	0	8	02/09/1999	Misra, et al.	424	484	
	US	5	8	6	9	1	0	1	02/09/1999	Moller, et al	424	489	
	US	5	8	8	3	1	0	3	03/16/1999	Burnside, et al.	514	262	
	US	5	8	9	1	0	4	5	04/06/1999	Myers	514	11	
	US	5	9	1	2	0	3	0	06/15/1999	Huzinec, et al.	426	3	
	US	5	9	1	9	4	8	1	07/06/1999	Saleki-Gerhardt, et al.	424	501	
	US	5	9	3	5	6	0	0	08/10/1999	Cherukuri, et al.	424	464	
	US	5	9	4	3	4	0	7	09/07/1999	McGuinness, et al.	424	184.1	
	US	5	9	5	2	0	0	4	09/14/1999	Rudnic, et al.	424	455	
	US	5	9	5	8	4	5	2	09/28/1999	Oshlack, et al.	424	457	
	US	5	9	6	9	1	6	1	10/12/1999	Oshlack, et al.	424	457	
	US	5	9	6	5	1	6	4	10/12/1999	Fuisz, et al.	424	489	
	US	6	9	7	0	3	7	3	10/26/1999	Yajima, et al.	424	489	
	US	5	9	5	0	9	4	0	11/09/1999	Raiden, et al.	424	464	
	US	6	0	1	0	7	1	8	01/04/2000	Al-Razzak, et al.	424	464	
	US	6	0	1	3	2	8	0	01/11/2000	Frisbee, et al.	424	464	
	US	6	0	4	8	5	4	1	04/11/2000	Mirsa, et al.	424	401	
	US	6	0	5	1	2	5	0	04/18/2000	Zettler, et al.	424	465	
	US	6	0	7	7	5	4	1	06/20/2000	Chen, et al.	424	480	
	US	6	0	8	3	4	3	0	07/04/2000	Fuisz, et al.	264	5	
	US	6	0	8	6	9	2	0	07/11/2000	Frisbee, et al.	424	489	
PH	US	6	0	9	0	8	3	0	07/18/2000	Myers, et al.	514	356	

SUPPLEMENTAL INFORMATION DISCLOSURE CITATION						ATTY. DOCKET NO. PC25240A				SERIAL NO. 10/763,340			
(Use several sheets if necessary) Page 4 of 7						APPLICANT Timothy A. Hagen, et al.							
						FILING DATE January 23, 2004				GROUP 1615			
pt	US	6	1	0	3	2	6	4	08/15/2000	Hoffmann, et al.	424	468	
	US	6	1	1	7	4	5	2	09/12/2000	Ahlgren, et al.	424	468	
	US	6	1	3	9	8	7	2	10/31/2000	Walsh	424	464	
	US	6	1	6	5	5	1	2	12/26/2000	Mezaache, et al.	424	489	
	US	6	2	2	1	3	6	2	04/21/2001	Breitenbach, et al.	424	400	
	US	6	2	6	1	5	9	9	07/17/2001	Oshlack, et al.	424	457	
	US	6	2	6	8	4	8	9	07/31/2001	Allen, et al.	536	7.4	
	US	6	2	7	0	8	0	4	08/07/2001	Getz, et al.	424	490	
	US	6	3	2	8	9	9	3	12/11/2001	Linder, et al	424	451	
	US	6	3	3	5	0	3	3	01/01/2002	Oshlack, et al.	424	457	
	US	6	3	8	3	5	1	0	05/07/2002	Linder, et al.	424	436	
	US	6	3	9	5	3	0	0	05/28/2002	Straub, et al.	424	489	
	US	6	5	5	1	6	1	6	04/22/2003	Notario, et al.	424	464	
	2001	0	0	0	3	5	9	0	06/14/2001	Joachim, et al.	424	465	
	2001	0	0	0	6	6	5	0	07/05/2001	Burnside, et al.	424	400	
	2002	0	0	0	9	4	3	3	01/24/2002	Curatolo, et al	424	94.1	
	2002	0	0	2	5	3	4	2	02/28/2002	Linder, et al	424	489	
	2002	0	0	4	4	9	6	8	04/18/2002	Van Lengerich	424	469	
	2005	0	0	2	6	8	5	1	02/03/2005	Danilovski, et al.	514	28	
	US	5	6	0	5	8	8	9	02/25/1997	Curatolo, et al.	514	29	
	2003	0	2	2	8	3	5	7	12/11/2003	Johnson, et al.	424	465	
	2003	0	1	6	5	5	6	3	09/04/2003	Murphy, et al.	424	465	
	2003	0	1	9	0	3	6	5	10/09/2003	Fergione, et al.	424	489	
	US	4	9	6	3	5	3	1	10/16/1990	Remington	514	29	
	2004	0	0	1	4	9	5	1	01/22/2004	Dumic et al	536	7.1	
	US	6	3	6	5	5	7	4	04/02/2002	Singer et al.	514	29	
	US	6	2	4	5	9	0	3	06/12/2001	Karimian, et al.	536	7.4	
pt	2004	0	1	2	1	0	0	3	06/24/2004	Chickering, III et al.	424	465	

SUPPLEMENTAL INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) Page 5 of 7									ATTY. DOCKET NO. PC25240A			SERIAL NO. 10/763,340		
APPLICANT Timothy A. Hagen, et al.														
FILING DATE January 23, 2004									GROUP 1615					

US	6	6	2	9	3	9	0	02/10/2004	Bernstein, et al.	424	501	
US	6	4	2	3	3	4	5	07/23/2002	Bernstein, et al.	424	501	
US	6	6	4	5	5	2	8	11/11/2003	Straub, Ket al.	424	489	

FOREIGN PATENT DOCUMENTS														
DOCUMENT NUMBER									DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
IN	1	8	7	4	8	7			24 May 00	Indian	A61K	9/10		
WO	9	1	0	7	1	7	1		30 May 91	International	A61K	9/16		
WO	9	4	0	0	1	1	2		06 Jan 94	International	A61K	9/22		
WO	9	4	2	7	5	5	7		8 Dec 94	International	A61			
WO	9	8	0	6	7	1	4		19 Feb 98	International	C07D	311/74		
WO	9	8	4	6	2	3	9		22 Oct 98	International	A61K	31/71		
WO	9	9	0	3	4	5	3		28 Jan 99	International	A61K	9/50		
WO	9	9	2	4	0	3	1		20 May 99	International	A61K	31/40		
WO	0	0	2	6	2	8	5		11 May 00	International	C08K	5/103		
WO	0	0	5	7	8	8	6		05 Oct 00	International	A61K	31/70		
WO	0	1	4	2	2	2	1		14 Jun 01	International	C07D	231/12		
WO	0	1	7	8	6	8	8		25 Oct 01	International	A61K	9/24		
WO	0	1	8	5	1	3	5		15 Nov 01	International	A61K	9/00		
WO	0	2	2	4	1	7	4		28 Mar 02	International	A61K	6/50		
WO	4	0	3	5	0	6	3		29 Apr 04	International	A61K	31/7048		
WO	3	0	3	2	9	2	2		24 Apr 03	International	A61K			
WO	4	0	0	9	6	0	8		29 Jan 04	International	C07H	17/00		
WO	3	0	6	8	1	9	1		21 Aug 03	International	A61K	9/14		
WO	4	0	8	7	0	9	6		14 Oct 04	International	A61K	9/00		
WO	3	1	0	5	8	1	0		24 Dec 03	International	A61K	9/20		
EP	0	0	8	0	3	4	1		01 Jun 83	EPO	A61K	9/22		
EP	0	1	0	9	2	5	3		23 May 84	EPO	C07H	17/00		



SUPPLEMENTAL INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) Page 6 of 7					ATTY. DOCKET NO. PC25240A					SERIAL NO. 10/763,340				
					APPLICANT Timothy A. Hagen, et al.									
					FILING DATE January 23, 2004					GROUP 1615				

PT	EP	0	5	8	2	3	9	6	09 Feb 94	EPO	A61K	31/71		
	EP	0	7	7	6	6	5	8	16 Feb 00	EPO	A61K	7/50		X
	EP	0	9	4	3	3	4	1	22 Sep 99	EPO	A61K	47/48		
	EP	1	1	2	7	5	8	0	29 Aug 01	EPO	A61K	47/10		
	EP	0	9	2	5	7	8	9	30 Jun 99	EPO	A61K	31/7052		
	EP	1	1	2	7	5	8	0	29 Aug 01	EPO	A61K	47/10		
	GB	2	0	6	6	0	7	0	08 Jul 81	United Kingdom	A61K	9/36		
PA	GB	2	0	9	1	0	9	7	28 Jul 82	United Kingdom	A61K	9/36		

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)														
PT			Barber, J., "Assignments of the ¹³ C and ¹ H NMR Spectra of Azithromycin in CDCl ₃ ," <i>Magnetic Resonance in Chemistry</i> 29:7(1991)740-743.											
			Barthelemy, P., et al., "Compritol® 888 ATO: An Innovative Hot-Melt Coating Agent for Prolonged-Release Drug Formulations," <i>Europ. J. Pharmaceut. and Biopharmaceutics</i> , 47(1999)87-90.											
			Bhagwatwar, H., et al., "Preparation of Drug-Containing Wax Microspheres Using a Melt Dispersion Technique," <i>Pharmaceutical Research</i> , 6:7(1989)S-177, Abstract No. PD 1201.											
			Breitenbach, J., et al., "Solid Dispersions by an Integrated Melt Extrusion System," <i>Proceed. Int'l Symp. Control. Re. Bioact. Materials</i> , 25(1998)804-805											
			Craig, D.Q.M., "The Physical Characterisation of Gelucire 50/13," <i>Bulletin Technique Gattefosse</i> , 89(1996)39-51.											
			DeMan, J.M., et al., "Thermal Analysis Microscopy for the Study of Phase Changes in Fats," <i>Food Microstructure</i> , 4(1985)233-239.											
			Eldem T., et al., "Polymorphic Behavior of Sprayed Lipid Micropellets and Its Evaluation by Differential Scanning Calorimetry and Scanning Electron Microscopy," <i>Pharmaceutical Research</i> , 8:2(1991)178-184.											
			Eldem, T., et al., "Optimization of Spray-Dried and -Congealed Lipid Micropellets and Characterization of Their Surface Morphology by Scanning Electron Microscopy," <i>Pharmaceutical Research</i> , 8:1(1991)47-54											
			Emas, M., and H. Nyqvist, "Methods of Studying Aging and Stabilization of Spray-Congeaed Solid Dispersions with Camauba Wax. 1. Microcalorimetric Investigation," <i>Int'l J. Pharmaceutics</i> , 197(2000)117-127.											
			Faham, A., et al., "Hot-Melt Coating Technology. I. Influence of Compritol 888 Ato and Granule Size on Theophylline Release," <i>Drug Dev. Industrial Pharm.</i> , 26:2(2000)167-176.											
			Follonier, N., et al., "Hot-Melt Extruded Pellets for the Sustained Release of Highly Dosed Freely Soluble Drugs," <i>Proceed. Intern. Symp. Control. Release Bioactive Materials</i> , 18(1991)578-579.											
			Forster, A., et al., "Characterization of Glass Solutions of Poorly Water-Soluble Drugs Produced by Melt Extrusion with Hydrophilic Amorphous Polymers," <i>J. Pharmacy Pharmacology</i> , 53(2001)303-315.											
			Foulds, G., et al., "The Absence of an Effect of Food on the Bioavailability of Azithromycin Administered as Tablets, Sachet or Suspension," <i>J. Antimicrobial Chemotherapy</i> , 37:Suppl. C(1996)37-44.											
			Gattefosse, "Gelucire® - Pharmaceutical Excipients for Oral Semi-Solid Formulations," Technical Dossier, 2 nd edition, Gattefosse s.a., Cedex, France (1996).											
			Ghali, E.S., et al., "Thermal Treatment of Beads with Wax for Controlled Release," <i>Drug Development and Industrial Pharmacy</i> , 15:9(1989)1311-1328.											
			Hancock, B.C., and G. Zografi, "The Relationship Between the Glass Transition Temperature and the Water Content of Amorphous Pharmaceutical Solids," <i>Pharmaceutical Research</i> , 11:4(1994)471-477.											
			Joachim, J., et al., "Le Compritol". Etudes Galenique, Physique et Statistique," <i>APGI</i> , IV(1989)291-296.											
			Johnson, D.E., et al., "A New Method for Coating Glass Beads for Use in Gas Chromatography of Chlorpromazine and Its Metabolites," Source unknown, and date unknown. (May be 1964-1965)											
PA			Jorgensen, K., et al., "Dissolution Stability of Multiparticulate Controlled Release Tablets," <i>Int'l J. Pharmaceutics</i> , 153(1997)1-11.											

SUPPLEMENTAL INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) Page 7 of 7		ATTY. DOCKET NO. PC25240A	SERIAL NO. 10/763,340
		APPLICANT Timothy A. Hagen, et al.	
		FILING DATE January 23, 2004	GROUP 1615

<div style="border: 1px solid black; width: 20px; height: 20px; margin: 0 auto;"></div>	<div style="border: 1px solid black; width: 20px; height: 20px; margin: 0 auto;"></div>	<div style="border: 1px solid black; width: 20px; height: 20px; margin: 0 auto;"></div>	<div style="border: 1px solid black; width: 20px; height: 20px; margin: 0 auto;"></div>	Meshall, M.M., et al., "Optimization of Theophylline Release from Tablets Containing Compritol," <i>S.T.P. Pharma Sciences</i> , 5:6(1995)429-434.
<div style="border: 1px solid black; width: 20px; height: 20px; margin: 0 auto;"></div>	<div style="border: 1px solid black; width: 20px; height: 20px; margin: 0 auto;"></div>	<div style="border: 1px solid black; width: 20px; height: 20px; margin: 0 auto;"></div>	<div style="border: 1px solid black; width: 20px; height: 20px; margin: 0 auto;"></div>	Perez, M. deLos A, et al., "Sustained Release Phenylpropanolamine Hydrochloride from Compritol ATO-888 Matrix," <i>Pharmaceutical Research</i> , 9:10(1992)S-162, Abstract No. PT6191.
<div style="border: 1px solid black; width: 20px; height: 20px; margin: 0 auto;"></div>	<div style="border: 1px solid black; width: 20px; height: 20px; margin: 0 auto;"></div>	<div style="border: 1px solid black; width: 20px; height: 20px; margin: 0 auto;"></div>	<div style="border: 1px solid black; width: 20px; height: 20px; margin: 0 auto;"></div>	Perez, M.A., et al., "Sustained Release Phenylpropanolamine Hydrochloride from ATO 888 Matrix," <i>PRHSJ</i> , 12:4(1993)263-267.
<div style="border: 1px solid black; width: 20px; height: 20px; margin: 0 auto;"></div>	<div style="border: 1px solid black; width: 20px; height: 20px; margin: 0 auto;"></div>	<div style="border: 1px solid black; width: 20px; height: 20px; margin: 0 auto;"></div>	<div style="border: 1px solid black; width: 20px; height: 20px; margin: 0 auto;"></div>	Perissutti, B., et al., "Solid Dispersions of Carbamazepine with Gelucire 44/14 and 50/13," <i>S.T.P. Pharma Sciences</i> , 10:6(2000)479-484.
<div style="border: 1px solid black; width: 20px; height: 20px; margin: 0 auto;"></div>	<div style="border: 1px solid black; width: 20px; height: 20px; margin: 0 auto;"></div>	<div style="border: 1px solid black; width: 20px; height: 20px; margin: 0 auto;"></div>	<div style="border: 1px solid black; width: 20px; height: 20px; margin: 0 auto;"></div>	Physician's Desk Reference, Information cited on ZITHROMAX® capsules (equivalent to 250 mg azithromycin), tablets (equivalent to 600 mg azithromycin), and oral suspension (equivalent to 1 g azithromycin).
<div style="border: 1px solid black; width: 20px; height: 20px; margin: 0 auto;"></div>	<div style="border: 1px solid black; width: 20px; height: 20px; margin: 0 auto;"></div>	<div style="border: 1px solid black; width: 20px; height: 20px; margin: 0 auto;"></div>	<div style="border: 1px solid black; width: 20px; height: 20px; margin: 0 auto;"></div>	Reilly, W.J. Jr., and J.B. Schwartz, "A Potential Controlled Release Wax Matrix Excipient," <i>Pharmaceutical Research</i> , 8:10(1991)98, supplement, Abstract No. PT6108.
<div style="border: 1px solid black; width: 20px; height: 20px; margin: 0 auto;"></div>	<div style="border: 1px solid black; width: 20px; height: 20px; margin: 0 auto;"></div>	<div style="border: 1px solid black; width: 20px; height: 20px; margin: 0 auto;"></div>	<div style="border: 1px solid black; width: 20px; height: 20px; margin: 0 auto;"></div>	Reis, R. and F. Moll, "Matrix Formation of Polyglycolic Acid Tablets by Annealing," <i>European J. Pharm. and Biopharm.</i> , 40:1(1994)14-18.
<div style="border: 1px solid black; width: 20px; height: 20px; margin: 0 auto;"></div>	<div style="border: 1px solid black; width: 20px; height: 20px; margin: 0 auto;"></div>	<div style="border: 1px solid black; width: 20px; height: 20px; margin: 0 auto;"></div>	<div style="border: 1px solid black; width: 20px; height: 20px; margin: 0 auto;"></div>	Rxdist.com, "Azithromycin," description of drug, categories, brand names, from internet website, March 14, 2001.
<div style="border: 1px solid black; width: 20px; height: 20px; margin: 0 auto;"></div>	<div style="border: 1px solid black; width: 20px; height: 20px; margin: 0 auto;"></div>	<div style="border: 1px solid black; width: 20px; height: 20px; margin: 0 auto;"></div>	<div style="border: 1px solid black; width: 20px; height: 20px; margin: 0 auto;"></div>	San Vicente, A., et al., "Effect of Aging on the Release of Salbutamol Sulfate from Lipid Matrices," <i>Int'l J. Pharmaceutics</i> , 208(2000)13-21.
<div style="border: 1px solid black; width: 20px; height: 20px; margin: 0 auto;"></div>	<div style="border: 1px solid black; width: 20px; height: 20px; margin: 0 auto;"></div>	<div style="border: 1px solid black; width: 20px; height: 20px; margin: 0 auto;"></div>	<div style="border: 1px solid black; width: 20px; height: 20px; margin: 0 auto;"></div>	Schwartz, J.B., et al., "A Potential Controlled Release Wax Matrix Excipient for Tablets," <i>Pharmaceutical Research</i> , 9:10(1992)S-162, Abstract No. PT6189
<div style="border: 1px solid black; width: 20px; height: 20px; margin: 0 auto;"></div>	<div style="border: 1px solid black; width: 20px; height: 20px; margin: 0 auto;"></div>	<div style="border: 1px solid black; width: 20px; height: 20px; margin: 0 auto;"></div>	<div style="border: 1px solid black; width: 20px; height: 20px; margin: 0 auto;"></div>	Schwartz, J.B., et al., "Preliminary Evaluation of Controlled Release Agents for Tablets," <i>Pharmaceutical Research</i> , 9:10(1992)S-162, Abstract No. PT6190.
<div style="border: 1px solid black; width: 20px; height: 20px; margin: 0 auto;"></div>	<div style="border: 1px solid black; width: 20px; height: 20px; margin: 0 auto;"></div>	<div style="border: 1px solid black; width: 20px; height: 20px; margin: 0 auto;"></div>	<div style="border: 1px solid black; width: 20px; height: 20px; margin: 0 auto;"></div>	Sugao, H., et al, "Taste Masking of Bitter Drug Powder without Loss of Bioavailability by Heat Treatment of Wax-Coated Microparticles," <i>J. Pharmaceutical Sci.</i> , 87:1(1998)96-100.
<div style="border: 1px solid black; width: 20px; height: 20px; margin: 0 auto;"></div>	<div style="border: 1px solid black; width: 20px; height: 20px; margin: 0 auto;"></div>	<div style="border: 1px solid black; width: 20px; height: 20px; margin: 0 auto;"></div>	<div style="border: 1px solid black; width: 20px; height: 20px; margin: 0 auto;"></div>	Thomsen, L.J., et al., "Prolonged Release Matrix Pellets Prepared by Melt Pelletization. I. Process Variables," <i>Drug Development and Industrial Pharmacy</i> , 19:15(1993)187-1887.
<div style="border: 1px solid black; width: 20px; height: 20px; margin: 0 auto;"></div>	<div style="border: 1px solid black; width: 20px; height: 20px; margin: 0 auto;"></div>	<div style="border: 1px solid black; width: 20px; height: 20px; margin: 0 auto;"></div>	<div style="border: 1px solid black; width: 20px; height: 20px; margin: 0 auto;"></div>	Wang, A.E. and J.B. Schwartz, "Effect of Temperature on Drug Release from Wax Matrix Tablets After Thermal Treatment," <i>Pharmaceutical Research</i> , 11:10(1994)S-155, Abstract No. 6099.
<div style="border: 1px solid black; width: 20px; height: 20px; margin: 0 auto;"></div>	<div style="border: 1px solid black; width: 20px; height: 20px; margin: 0 auto;"></div>	<div style="border: 1px solid black; width: 20px; height: 20px; margin: 0 auto;"></div>	<div style="border: 1px solid black; width: 20px; height: 20px; margin: 0 auto;"></div>	Zhang, Y.-E., et al., "Effect of Processing Methods and Heat Treatment on the Formation of Wax Matrix Tablets for Sustained Drug Release," <i>Pharm. Dev. Technol.</i> , 6:2(2001)131-144.
<div style="border: 1px solid black; width: 20px; height: 20px; margin: 0 auto;"></div>	<div style="border: 1px solid black; width: 20px; height: 20px; margin: 0 auto;"></div>	<div style="border: 1px solid black; width: 20px; height: 20px; margin: 0 auto;"></div>	<div style="border: 1px solid black; width: 20px; height: 20px; margin: 0 auto;"></div>	Arguendas, A., "Single Dose Therapy in Otitis Media," <i>Clinical Microbiology and Infection</i> , Abstract, S130, vol. 5, Supplemental 3, (1999)
<div style="border: 1px solid black; width: 20px; height: 20px; margin: 0 auto;"></div>	<div style="border: 1px solid black; width: 20px; height: 20px; margin: 0 auto;"></div>	<div style="border: 1px solid black; width: 20px; height: 20px; margin: 0 auto;"></div>	<div style="border: 1px solid black; width: 20px; height: 20px; margin: 0 auto;"></div>	Block, S., et al., "Single-Dose Azithromycin (30 mg/kg) in Acute Otitis Media," ICAAC, New Orleans, LA, Sept 7-10, 2003, Abstract 174
<div style="border: 1px solid black; width: 20px; height: 20px; margin: 0 auto;"></div>	<div style="border: 1px solid black; width: 20px; height: 20px; margin: 0 auto;"></div>	<div style="border: 1px solid black; width: 20px; height: 20px; margin: 0 auto;"></div>	<div style="border: 1px solid black; width: 20px; height: 20px; margin: 0 auto;"></div>	Curatolo, W., et al., "Site-Specific Absorption and Toleration of Azithromycin," Proceedings Intern. Symposium Rel. Bioact. Mater., 23, 1996
<div style="border: 1px solid black; width: 20px; height: 20px; margin: 0 auto;"></div>	<div style="border: 1px solid black; width: 20px; height: 20px; margin: 0 auto;"></div>	<div style="border: 1px solid black; width: 20px; height: 20px; margin: 0 auto;"></div>	<div style="border: 1px solid black; width: 20px; height: 20px; margin: 0 auto;"></div>	Luke, D.R., et al, "Clinical Pharmacology of Azithromycin Given at Various Sites Along the Gastrointestinal Tract in Healthy Subjects," pp. 464-468
<div style="border: 1px solid black; width: 20px; height: 20px; margin: 0 auto;"></div>	<div style="border: 1px solid black; width: 20px; height: 20px; margin: 0 auto;"></div>	<div style="border: 1px solid black; width: 20px; height: 20px; margin: 0 auto;"></div>	<div style="border: 1px solid black; width: 20px; height: 20px; margin: 0 auto;"></div>	Physicians Desk Reference, "Appendix A Summary of Pediatric Suspension Commercial Products," 55 th edition, Phase III Clinical Dosage Form Nomination, pp 19 and 28 (2001)
<div style="border: 1px solid black; width: 20px; height: 20px; margin: 0 auto;"></div>	<div style="border: 1px solid black; width: 20px; height: 20px; margin: 0 auto;"></div>	<div style="border: 1px solid black; width: 20px; height: 20px; margin: 0 auto;"></div>	<div style="border: 1px solid black; width: 20px; height: 20px; margin: 0 auto;"></div>	Pfizer, Inc., Zithromax [package insert], "Zithromax (azithromycin tablets) and (azithromycin for oral suspension)," www.pfizer.com/download/uspi_zithromax.pdf (2004)

EXAMINER <div style="font-family: cursive; font-size: 1.5em; margin-top: 10px;">  </div>	DATE CONSIDERED <div style="font-size: 1.5em; margin-top: 10px;">  </div>
<small>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>	



INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)	ATTY. DOCKET NO. PC25240A	SERIAL NO. 10/763,340
	APPLICANT Timothy A. Hagen, et al.	
	FILING DATE January 23, 2004	GROUP 1615

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
PJ	US	5	1	0	9	6	4	5	12/8/92	Shukla, et al.	424	499	
	US	5	6	3	3	0	0	6	5/27/97	Catania, et al.	424	441	
	US	5	6	0	5	8	0	9	2/25/97	Curatolo, et al.	514	29	
	US	5	7	0	5	1	0	0	1/6/98	Broad, et al.	424	465	
	US	5	7	4	7	0	5	0	5/5/98	Tipton, et al.	424	423	
	US	5	7	6	8	8	5	9	5/30/00	Curatolo, et al.	424	490	
	US	6	2	4	5	3	6	3	6/19/01	Patel, et al.	424	497	
	US	6	5	0	0	4	5	9	12/31/02	Chhabra, et al.	424	474	
	US	6	5	6	9	4	6	3	5/27/03	Patel, et al.	424	497	
	US	6	5	7	6	2	5	8	6/10/03	Kofler, et al.	424	458	
	US	6	6	8	2	7	5	9	1/27/04	Lim, et al.	424	468	
PA	US	6	6	9	2	7	6	7	2/17/04	Burnside, et al.	424	489	

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER									DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
									m/d/y				YES	NO
PA	WO	9	5	0	9	6	0	1	4/13/95	International	A61K	7/16		
	WO	9	8	1	8	6	1	0	5/7/98	International	B29C	47/04		
	WO	9	8	5	6	3	5	7	12/17/98	International	A61K	9/20		
	WO	0	3	1	8	0	3	1	3/6/03	International	A61K	31/7052		
	WO	0	3	3	7	3	0	4	5/8/03	International	A61K	9/16		
	WO	0	3	5	3	4	0	2	7/3/03	International	A61K	9/00		
	WO	0	3	6	3	8	3	4	8/7/03	International	A61K	9/16		
PA	WO	0	4	0	0	8	6	5	12/31/03	International	A61K	31/7048		

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

PJ		Curatolo, et al., US Patent Application Publication No. US 2002/0009433, Application No. 09/788,886, Published 1/24/02
PA		Dunne, U.S. Patent Application Publication No. US 2004/0023898, Application No. 10/628,102, Published 2/5/04

EXPRESS MAIL NO. EV271824289 US.



INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		ATTY. DOCKET NO. PC25240A	SERIAL NO. 10/763,340
		APPLICANT Timothy A. Hagen, et al.	
		FILING DATE January 23, 2004	GROUP 1615
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
PA		Foulds, G., et al., "The effects of an antacid or cimetidine on the serum concentrations of azithromycin", J. Clin. Pharmacol. 1991 Feb; 31(2): 164-7 (Abstract)	
		Arnsden, G.W., et al., "Serum and WBC pharmacokinetics of 1500 mg of azithromycin when given either as a single dose or over a 3 day period in healthy volunteers", J. Antimicrobial Chemotherapy (2001), 47(1), 61-66 (Abstract)	
		Zithromax® azithromycin tablet 250 mg, Quantitative Composition of the Tablet Blend	
		Zithromax® azithromycin for oral suspension composition 200 mg/5mL, 200mg/5mL Drug Product	
		Zithromax® azithromycin for oral suspension composition 1 gram sachet, Quantitative Composition of the Drug Product	
		Zithromax® azithromycin for oral suspension composition 100 mg/5mL, Quantitative Compositions of the Drug Products	
		Zithromax® (azithromycin tablets and azithromycin for oral suspension), Full U.S. Prescribing Information, 70-5179-00-4	
		Zithromax® (azithromycin capsules) (azithromycin tablets) and (azithromycin for oral suspension), Full U.S. Prescribing Information, 69-4763-00-9	
PA		Food and Drug Administration Center for Drug Evaluation and Research Approved Drug Products with Therapeutic Evaluations, 24 th Edition, Orange Book Listings of Azithromycin Dosage Forms	
EXAMINER		DATE CONSIDERED	
		5-16-2005	
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

Conforms with FORM PTO-FB-A820

INFORMATION DISCLOSURE

EXPRESS MAIL NO. EV271824289 US